FA
RNAC icon

Fedenia Advisers’s Cartesian Therapeutics RNAC Stock Holding History

Fedenia Advisers’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$297K Buy
+28,509
New +$211K 0.07% 104

Other funds holding RNAC

PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
SIC
SJS Investment Consulting Sylvania, Ohio $919M AUM 23.4% 1-Year Est. Return

Fedenia Advisers's RNAC Position: Q2 2026 in Review

Fedenia Advisers opened a new position in Cartesian Therapeutics (RNAC) in Q2 2026: 28,509 shares worth $297K. The stake represents 0.07% of the portfolio and ranks #104 among its holdings.

10 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • Fedenia Advisers held 28,509 shares of Cartesian Therapeutics worth $297K as of Q2 2026.
  • Cartesian Therapeutics was a new Fedenia Advisers position in Q2 2026.
  • Cartesian Therapeutics made up 0.07% of Fedenia Advisers's portfolio in Q2 2026, its #104 holding.
  • 10 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Fedenia Advisers's 13F filing for Q2 2026, filed 22 Jul 2026.